Novartis AG Stock News

When a company's return on equity (ROE) ratio outperforms most of its peers, it indicates the company has been very efficient in generating earnings.

Novartis' (NVS) asciminib gets Breakthrough Therapy tag by the FDA for the treatment of adult patients with Ph+ CML in chronic phase, previously treated with two or more tyrosine kinase inhibitors.

Bolt Biotherapeutics has filed proposed terms for a $150 million IPO. The firm is developing antibody conjugate treatments for various cancers.

Week In Review: Matridx Raises $32 Million For AI/CRISPR-Cas Pathogen Metagenomics Diagnostic Devices

The digital press release with multimedia content can be accessed here:

Jan.28 -- Novartis AG CEO Vas Narasimhan tells Bloomberg Television that the drugmaker is in talks with "a range of different players" to help produce other companies' Covid-19 vaccines or treatmen

Novartis (NVS) reports dismal fourth-quarter results as the pandemic affected sales. The outlook for 2021 also indicates challenges ahead.

Novartis AG (NVS) CEO Vas Narasimhan on Q4 2020 Results - Earnings Call Transcript

Vas Narasimhan, Novartis CEO, joins 'Closing Bell' to talk about developing a new Covid-19 treatment that uses something called DARPin (Designed Ankyrin Repeat Proteins) "We hope by the summer to get

Allogene Therapeutics (NASDAQ: ALLO) shares are trading higher Tuesday after Stifel upgraded the stock from Hold to Buy and raised its price target from $33 to $43 per share. Allogene is a U.S.-based

The Swiss pharmaceutical company's stock slipped on Tuesday, as it offered cautious guidance.

Shares of Novartis (NYSE:NVS) decreased 3.8% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 1.52% over the past year to $1.34, which missed

Novartis Chief Executive Vas Narasimhan on Tuesday renewed his commitment to his Sandoz generic unit where sales growth in 2020 stagnated due to reduced hospital stays during the COVID-19 pandemic.

Jan.26 -- Vas Narasimhan, chief executive officer at Novartis AG, discusses his outlook for the second half of the year, the vaccine rollout and the long-term impact of Covid-19. He speaks on “Bloom